The latest biotech news

News and Trends 18 Sep 2023

Rebuilding relations: U.K. rejoins Horizon Europe to boost funding opportunities

The U.K. is rejoining the European Union’s (EU’s) $100 billion research program Horizon Europe, after being locked out of the deal amid post Brexit tensions for more than two years. This comes after months of negotiations between the U.K. government and the EU, in an attempt to broaden opportunities for researchers in the U.K.. British […]

September 18, 2023 - 5 minutesmins - By Roohi Mariam Peter

News and Trends 31 Jul 2023

Biogen acquiring Reata Pharmaceuticals for $7.3B

Biogen Inc. and Reata Pharmaceuticals, Inc. have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Reata has made advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. Reata’s FDA-approved SKYCLARYS (omaveloxolone) is […]

July 31, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 28 Jul 2023

FDA grants breakthrough therapy designation to Duchenne muscular dystrophy treatment

The U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to NS Pharma Inc.’s NS-089/NCNP-02, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy. The breakthrough designation is based on results from a first-in-human, investigator-initiated clinical trial conducted in Japan. In June 2023, NS-089/NCNP-02 was granted Rare […]

July 28, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 28 Jul 2023

Could a natural sweetener from hydrangeas treat Alzheimer’s disease?

Amyloid β (Aβ) aggregation is primarily responsible for the development of Alzheimer’s disease (AD). In a new mouse model study, South Korean researchers investigated the effect of phyllodulcin — a natural sweetener found in the hydrangea plant — in inhibiting Aβ accumulation. The results suggest that phyllodulcin effectively inhibits Aβ accumulation and decomposes the pre-aggregated […]

July 28, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 28 Jul 2023

New CHAIN Biotech funding to aid CADD therapeutic platform

CHAIN Biotechnology Limited has developed a therapeutic approach based on engineering a probiotic strain of Clostridium to deliver oral vaccines and therapeutics. Its Clostridium Assisted Drug Development platform (CADD) technology is a live therapeutic that employs a triple mode of action, incorporating mucosal and systemic immune responses alongside microbiome enhancement, and is delivered via stable, […]

July 28, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Jul 2023

Recbio shingles vaccine clinical trial approved

Jiangsu Recbio Technology Co., Ltd. has received notice of acceptance from China’s National Medical Products Administration (NMPA) to start a clinical trial for its self-developed novel adjuvanted recombinant shingles vaccine, REC610. Within 60 days from the date of acceptance, the company may carry out clinical trials in accordance with the submitted plan if no negative […]

July 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Jul 2023

Epsilogen completes first clinical trial of IgE antibody to treat cancer

Epsilogen, a producer of immunoglobulin E (IgE) antibodies to treat cancer, has published the final phase I data from the first ever clinical trial of an IgE antibody therapeutic. The results were published in Nature Communications. MOv18 IgE is Epsilogen’s lead IgE antibody drug candidate and binds to anti-folate receptor (FRα), a well validated target […]

July 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Jul 2023

Medicxi announces $400M fund for life science companies

Medicxi, a European life sciences investment firm, has launched its $400 million Medicxi IV fund. The new fund will support companies with clear product visions to deliver transformative therapies for patients. Medicxi’s investments have resulted in the development of several marketed and late-stage development drugs, including Daratumumab (Genmab/Johnson & Johnson), Blincyto (Amgen), Alunbrig (Takeda), Voquezna […]

July 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 26 Jul 2023

Diabetes drug could promote healthy aging

A research team from the School of Public Health, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has provided genetic evidence that metformin might promote healthy aging using a cohort study of more than 300,000 participants of European descent (UK Biobank). The proof-of-concept work supports further clinical research into the drug repositioning […]

July 26, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 25 Jul 2023

Triastek sees positive results from printed oral treatment for ulcerative colitis

Triastek, Inc. has completed its first in human study of its third 3D printing drug product, T21, designed to treat moderate to severe ulcerative colitis (UC). Imaging results from the study confirmed that T21 tablets are precisely delivered and released to the target site – the colon – for the drug release. The administration of […]

July 25, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 25 Jul 2023

Can the microbiome help the fight against infections?

Animals and humans coexist with a vast array of microorganisms known as the microbiome, forming a relationship that can range from mutually beneficial to pathogenic. To safeguard against harmful pathogens and maintain the presence of beneficial microorganisms, animals have evolved various defenses.One is small antimicrobial peptides (AMPs), small peptides that combat invading microbes. AMPs are […]

July 25, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 25 Jul 2023

Molecure raises $12M and gets FDA clearance for pulmonary sarcoidosis trial

Molecure S.A. has received clearance from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application to conduct phase II clinical testing of OATD-01. The announcement follows the company closing a secondary public offering and entering into subscription agreements for all 2,776,000 H-shares offered by way of private placement, within the […]

July 25, 2023 - 4 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Rebuilding relations: U.K. rejoins Horizon Europe to boost funding opportunities

Biogen acquiring Reata Pharmaceuticals for $7.3B

FDA grants breakthrough therapy designation to Duchenne muscular dystrophy treatment

Could a natural sweetener from hydrangeas treat Alzheimer’s disease?

New CHAIN Biotech funding to aid CADD therapeutic platform

Recbio shingles vaccine clinical trial approved

Epsilogen completes first clinical trial of IgE antibody to treat cancer

Medicxi announces $400M fund for life science companies

Diabetes drug could promote healthy aging

Triastek sees positive results from printed oral treatment for ulcerative colitis

Can the microbiome help the fight against infections?

Molecure raises $12M and gets FDA clearance for pulmonary sarcoidosis trial

Subscribe to our newsletter to get the latest biotech news!